Skip to main content

letter

. 1993 Jul;36(1):87–88. doi: 10.1111/j.1365-2125.1993.tb05899.x

Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications.

M Barry, D Back, S Ormesher, N Beeching, F Nye

PMCID: PMC1364562 PMID: 8373717

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Cooney D. A., Ahluwalia G., Mitsuya H., Fridland A., Johnson M., Hao Z., Dalal M., Balzarini J., Broder S., Johns D. G. Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol. 1987 Jun 1;36(11):1765–1768. doi: 10.1016/0006-2952(87)90235-8. [DOI] [PubMed] [Google Scholar]
Hartman N. R., Yarchoan R., Pluda J. M., Thomas R. V., Marczyk K. S., Broder S., Johns D. G. Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther. 1990 May;47(5):647–654. doi: 10.1038/clpt.1990.86. [DOI] [PubMed] [Google Scholar]
Hirsch M. S. Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. J Infect Dis. 1990 May;161(5):845–857. doi: 10.1093/infdis/161.5.845. [DOI] [PubMed] [Google Scholar]
McDougal J. S., Martin L. S., Cort S. P., Mozen M., Heldebrant C. M., Evatt B. L. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. J Clin Invest. 1985 Aug;76(2):875–877. doi: 10.1172/JCI112045. [DOI] [PMC free article] [PubMed] [Google Scholar]
Simmonds H. A., Fairbanks L. D., Morris G. S., Webster D. R., Harley E. H. Altered erythrocyte nucleotide patterns are characteristic of inherited disorders of purine or pyrimidine metabolism. Clin Chim Acta. 1988 Feb 15;171(2-3):197–210. doi: 10.1016/0009-8981(88)90145-3. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES